A study to assess the effect of intensive uric acid (UA) lowering therapy with RDEA3170, febuxostat, dapagliflozin on urinary excretion of UA

Trial Identifier: D5495C00001
Sponsor: AstraZeneca
Collaborator:
Contract Research Organization: USA
PAREXEL Early Phase Clinical Unit Baltimore
PAREXEL Early Phase Clinical Unit-Los Angeles
Clinical Laboratory: USA
Harbor Hospital Laboratory
GenX Laboratories Inc.
Analytical Laboratory (Pharmacokinetic Sample Analysis): USA
Covance Bioanalytical Services, LLC
NCTID:: NCT03316131
Start Date: October 2017
Primary Completion Date: July 2018
Study Completion Date: July 2018

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Translation

Trial Locations